Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the ...
Seeking Alpha

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration ...
Nasdaq

Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness

Emergent BioSolutions Inc. announced a contract modification with the U.S. Department of Health and Human Services to provide additional doses of its smallpox treatment, CNJ-016® (Vaccinia Immune ...
Seeking Alpha

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune Globulin ...
Morningstar

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance ...

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ...
Eagle-Tribune

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin ...

GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for ...
Morningstar

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research ...
Nasdaq

Emergent BioSolutions Wins $30 Mln Contract Modicfication To Supply CYFENDUS

(RTTNews) - Emergent BioSolutions Inc. (EBS), Tuesday announced that the company has secured contract modification from the Biomedical Advanced Research and Development Authority to supply CYFENDUS, a ...
ABC News

In wake of Emergent BioSolutions' vaccine problems, CEO's stock trades come into focus

Quality control errors led millions of potential vaccines to be ruined. For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. Standing ...